|
Demographics
|
|
Male gender; n (%)
|
20 (25)
|
9 (22)
|
|
Age (years); median (IQR)
|
38.6 (34.9–40.7)
|
37.7 (34.8–40.5)
|
|
Disease duration (years); median (IQR)
|
29.3 (28.3–30.6)
| |
|
Onset age (years); median (IQR)
|
8.9 (4.9–11.8)
| |
|
JIA subtype distribution
|
|
Systemic arthritis; n (%)
|
4 (5)
| |
|
RF negative polyarthritis; n (%)
|
11 (14)
| |
|
RF positive polyarthritis; n (%)
|
5 (6)
| |
|
Persistent oligoarthritis; n (%)
|
14 (17)
| |
|
Extended oligoarthritis; n (%)
|
13 (16)
| |
|
Entesitis related arthritis; n (%)
|
18 (22)
| |
|
Psoriatic arthritis; n (%)
|
14 (17)
| |
|
Unclassified arthritis; n (%)
|
2 (3)
| |
|
Current medication at 29-year follow-up
|
|
Anti-TNF; n (%)
|
25 (31)
| |
|
Metotrexat; n (%)
|
19 (24)
| |
|
NSAIDs daily; n (%)
|
23 (28)
| |
|
Prednisolone; n (%)
|
5 (6.2)
| |
|
Cardiovascular risk factors
|
|
BMI (kg/m2); mean (SD)
|
25.7 (5.0)
|
25.3 (3.9)
|
|
Waist circumference (cm); mean (SD)
|
92.7 (12.7)
|
92.7 (9.0)
|
|
Daily smokers; n (%)
|
18 (22)
|
5 (12)
|
|
CVD in first degree relative; n (%)
|
46 (57)
|
19 (46)
|
|
Hypertension; n (%)
|
9 (11)
|
0 (0)*
|
|
Myocardial infarction; n (%)
|
1 (1)
|
0 (0)
|
|
Total cholesterol (mmol/L); mean (SD)
|
4.9 (1.1)
|
4.9 (0.8)
|
|
LDL cholesterol (mmol/L); mean (SD)
|
3.0 (1.0)
|
3.0 (0.8)
|
|
hs-CRP (mg/L); median (IQR)
|
1.8 (0.7–5.0)
|
0.7 (0.0–1.9)*
|
|
Insulin resistance
|
1.1 (1.1)
|
0.9 (0.6)
|
